Key result
Standard heart failure treatment is recommended for peripartum cardiomyopathy, with therapy adjusted to ensure fetal safety during pregnancy.
This review provides a comprehensive clinical guide for the diagnosis and practical management of peripartum cardiomyopathy, highlighting the need for pregnancy-adjusted heart failure therapies and multidisciplinary care.
Supports individualized peripartum cardiomyopathy therapy in pregnancy; leaves open prospective validation of outcomes.
Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy that causes systolic heart failure (HF) in previously healthy young women. Despite latest remarkable achievement, unifying pathophysiologic mechanism is not well established. Considering close temporal relationship to pregnancy, the recent prolactin theory is promising. Abnormal short form of 16-kDa prolactin may be produced in the oxidative stress milieu, show anti-angiogenic effect and damage cardiovascular structure in late pregnancy. Future study is needed to determine whether abnormal prolactin system is useful as a biomarker for diagnosis and therapy of PPCM. Diagnosis is made based on the finding of left ventricular systolic dysfunction after excluding other causes of HF. A multidisciplinary team approach is essential for acute HF, antepartum, labor and postpartum care. Recovery from left ventricular dysfunction is critical for prognosis. As PPCM can recur and cause serious clinical events, subsequent pregnancy is not recommended. This review focuses on the practical management of PPCM.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) conducted a review in Peripartum cardiomyopathy. Management of peripartum cardiomyopathy was evaluated. Standard heart failure treatment is recommended for peripartum cardiomyopathy, with therapy adjusted to ensure fetal safety during pregnancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: